Anne Katrin Schlag's guest appearances

Anne Katrin Schlag

The Cannabis Conversation | Medical Cannabis | CBD | Hemp

OwlTail

Mags Houston

This week we’re excited to welcome Mags Houston and Dr. Anne Katrin Schlag from Drug Science - independent science led drugs charity based in London.Together, we explore how ProjectTwenty21 is progressing, some of the initial findings from the participating patient set, alongside digging into the true value of real-world data as a form of medical evidence opposed to randomised controlled trials.The Cannabis Conversation is sponsored by Lumino  - a boutique HR and Recruitment Agency specialising in building high performance teams for the European Cannabis Industry. They work in three main verticals: Commercial, Medical and Plant Facing.Get in touch at www.luminorecruit.com/📚 VIEW SHOW NOTES AND EXTRAS:https://www.canverse.global/shownotes/e149About Dr Anne Katrin Schlag - Head of Research at Drug Science Dr Anne Katrin Schlag is a Chartered Psychologist and Head of Research at Drug Science (https://drugscience.org.uk). She leads the research for the Drug Science Medical Cannabis Working Group, focusing on controversies surrounding medical cannabis, the improvement of patient access, and the continued development of education and stakeholder communication about medical cannabis. Dr Schlag is currently working on progressing the scientific evidence base of medical cannabis to include Patient Reported Outcomes, observational studies (such as T21) and the application of Multi-Criteria Decision Analysis to assess the benefits and safety of medical cannabis.She holds Honorary Fellowships at both Imperial College London and King’s College London, chairs the research subgroup of the Cannabis Industry Council, and is scientific advisor to the Primary Care Cannabis Network.  About Mags Houston - Head of T21 at Drug ScienceAs Head of Project Twenty21, Mags is the operational lead for Drug Science’s medical cannabis observational study, helping to raise awareness amongst patients and prescribers, build more evidence by attracting more patients and prescribers to actively join the project, and educate the public about the growing evidence surrounding medical cannabis for treating a range of conditions. Alongside her role on T21, she volunteers for Heroic Hearts Project UK, a not-for-profit that helps veterans suffering with PTSD by providing retreats and education in psychedelic therapy. She also curates and hosts events for The Psychedelic Society (UK) around drug policy, psychedelic science and mental health treatment. Mags’ mission is to shift the mainstream narrative around drugs by helping to provide education and challenging UK drug policy, so that therapies and medicines that are currently not accessible to patients might be made available on the NHS and prescribed to the people who desperately need them.ResourcesDrug Science’s Website:  https://www.drugscience.org.ukProject Twenty21: https://www.drugscience.org.uk/project-twenty-21/Join Anne on LinkedIn: https://www.linkedin.com/in/anne-katrin-schlag-3886a4/Join Mags on LinkedIn: https://www.linkedin.com/in/ACoAAAOCG4IBadL6I3LJNez4_WtaJaWoemfjZlQ/

This week we’re excited to welcome Mags Houston and Dr. Anne Katrin Schlag from Drug Science - independent science led drugs charity based in London.Together, we explore how ProjectTwenty21 is progressing, some of the initial findings from the participating patient set, alongside digging into the true value of real-world data as a form of medical evidence opposed to randomised controlled trials.The Cannabis Conversation is sponsored by <a href="https://luminorecruit.com/?utm_source=TCC&amp;utm_medium=podcast" rel="nofollow" target="_blank">Lumino</a>  - a boutique HR and Recruitment Agency specialising in building high performance teams for the European Cannabis Industry. They work in three main verticals: Commercial, Medical and Plant Facing.Get in touch at<a href="https://luminorecruit.com/?utm_source=TCC&amp;utm_medium=podcast" rel="nofollow" target="_blank"> www.luminorecruit.com/</a> 📚 VIEW SHOW NOTES AND EXTRAS:<a href="https://www.canverse.global/shownotes/e145" rel="nofollow" target="_blank">https://www.canverse.global/shownotes/e149</a> About Dr Anne Katrin Schlag - Head of Research at Drug Science Dr Anne Katrin Schlag is a Chartered Psychologist and Head of Research at Drug Science (<a href="https://drugscience.org.uk" rel="nofollow" target="_blank">https://drugscience.org.uk</a>). She leads the research for the Drug Science Medical Cannabis Working Group, focusing on controversies surrounding medical cannabis, the improvement of patient access, and the continued development of education and stakeholder communication about medical cannabis. Dr Schlag is currently working on progressing the scientific evidence base of medical cannabis to include Patient Reported Outcomes, observational studies (such as T21) and the application of Multi-Criteria Decision Analysis to assess the benefits and safety of medical cannabis.She holds Honorary Fellowships at both Imperial College London and King’s College London, chairs the research subgroup of the Cannabis Industry Council, and is scientific advisor to the Primary Care Cannabis Network.  About Mags Houston - Head of T21 at Drug ScienceAs Head of Project Twenty21, Mags is the operational lead for Drug Science’s medical cannabis observational study, helping to raise awareness amongst patients and prescribers, build more evidence by attracting more patients and prescribers to actively join the project, and educate the public about the growing evidence surrounding medical cannabis for treating a range of conditions. Alongside her role on T21, she volunteers for Heroic Hearts Project UK, a not-for-profit that helps veterans suffering with PTSD by providing retreats and education in psychedelic therapy. She also curates and hosts events for The Psychedelic Society (UK) around drug policy, psychedelic science and mental health treatment. Mags’ mission is to shift the mainstream narrative around drugs by helping to provide education and challenging UK drug policy, so that therapies and medicines that are currently not accessible to patients might be made available on the NHS and prescribed to the people who desperately need them. ResourcesDrug Science’s Website:  <a href="https://www.drugscience.org.uk" rel="nofollow" target="_blank">https://www.drugscience.org.uk</a>Project Twenty21: <a href="https://www.drugscience.org.uk/project-twenty-21/" rel="nofollow" target="_blank">https://www.drugscience.org.uk/project-twenty-21/</a>Join Anne on LinkedIn: <a href="https://www.linkedin.com/in/anne-katrin-schlag-3886a4/" rel="nofollow" target="_blank">https://www.linkedin.com/in/anne-katrin-schlag-3886a4/</a>Join Mags on LinkedIn: <a href="https://www.linkedin.com/in/ACoAAAOCG4IBadL6I3LJNez4_WtaJaWoemfjZlQ/" rel="nofollow" target="_blank">https://www.linkedin.com/in/ACoAAAOCG4IBadL6I3LJNez4_WtaJaWoemfjZlQ/</a>